Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III β-tubulin

International Journal of Gynecological Pathology

Volumn 27, Issue 2, 2008, Pages 207-212

  Umezu, Tomokazu ^a   Shibata, Kiyosumi ^a   Kajiyama, Hiroaki ^a   Terauchi, Mikio ^a   Ino, Kazuhiko ^a   Nawa, Akihiro ^a   Kikkawa, Fumitaka ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Class III tubulin taxol resistance histology; Ovarian cancer

Indexed keywords

BETA TUBULIN; PACLITAXEL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; ENDOMETRIOID CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, ENDOMETRIOID; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; PACLITAXEL; TUBULIN;

EID: 41349121211     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/PGP.0b013e318156c838     Document Type: Article

References (29)

1. Kurman RJ, ed. Blaustein's Pathology of the Female Genital Tract, 2nd ed. New York: Springer-Verlag 1994:705-82 [chapter 18].
2. Makar AP, Baekelandt M, Trope CG, et al. The prognostic significance of residual disease, FIGO substage, tumor histology and grade with FIGO stage III ovarian cancer. Gynecol Oncol 1995;56:175-80.
3. Silverberg SG. Prognostic significance of pathologic features of ovarian carcinoma. Curr Top Pathol 1989;78:85-100.
4. Recio FO, Piver MS, Hempling RE, et al. Lack of improved survival plus increased in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy. Cancer 1996;78:2157-63.
5. Kavallaris M, Kuo DYS, Burkhart CA, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes. J Clin Invest 1997;100:1282-93.
6. Derry WB, Wilson L, Khan IA, et al. Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified β-tubulin isotypes. Biochemistry 1997;36:3554-62.
7. Hari M, Yang H, Zeng C, et al. Expression of class III β-tubulin reduces microtubule assembly and confers resistance to paclitaxel. Cell Motil Cytoskeleton 2003;56:45-56.
8. Dumontet C, Isaac S, Souquet PJ, et al. Expression of class III β-tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer 2005;92:25-30.
9. Rosell R, Scagliotti G, Danenberg KD, et al. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 2003;22:3548-53.
10. Seve P, Mackey J, Isaac S, et al. Class III β-tubulin expression in tumor cells predicts response and outcome in patients with nonsmall cell lung cancer receiving paclitaxel. Mol Cancer Ther 2005;4:2001-7.
11. Mozzetti S, Ferlini C, Concolino P, et al. Class III β-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 2005;11:298-305.
12. Ferrandina G, Zannoni GF, Martinelli E, et al. Class III β-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res 2006;12:2774-79.
13. Suzuki Y, Shibata K, Kikkawa F, et al. Possible role of placental leucine aminopeptidase in the antiproliferative effect of oxytocin in human endometrial adenocarcinoma. Clin Cancer Res 2003;9:1528-34.
14. Hoskins WJ, Bundy BN, Thigpen JT, et al. The influence of cytoreductive surgery on recurrence-free interval and survival in small volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1992;47:167-71.
15. Hoskins WJ, McGuire WP, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994;170:974-80.
16. Fujita M, Enomoto T, Murata Y. Genetic alterations in ovarian carcinoma: with specific reference to histological subtypes. Mol Cell Endocrinol 2003;202:97-9.
17. Tsuchiya A, Sakamoto M, Yasuda J, et al. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol 2003;163:2503-12.
18. Horwitz SB, Lothstein L, Manfradi JJ, et al. Taxol: mechanisms of action and resistance. Ann N Y Acad Sci 1986;466:733-44.
19. Yokoyama Y, Sato S, Fukushi Y, et al. Significance of multidrug-resistant proteins in predicting chemotherapy response and prognosis in epithelial ovarian cancer. J Obstet Gynaecol Res 1999;25:387-94.
20. Baekelandt MM, Holm R, Nesland JM, et al. P-Glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer. Anticancer Res 2000;20:1061-7.
21. Penson RT, Oliva E, Skates SJ, et al. Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol 2004;93:98-106.
22. Schneider J, Jimenez E, Marenbach K, et al. Coexpression of the MDR1 gene and HSP27 in human ovarian cancer. Anticancer Res 1998;18:2967-71.
23. Goff BA, Ries JA, Els LP, et al. Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure. Gynecol Oncol 1998;70:378-85.
24. Giannakakou P, Sackett DL, Kang YK, et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997;272:17118-25.
25. Tsurutani J, Komiya T, Uejima H, et al. Mutational analysis of the beta-tubulin gene in lung cancer. Lung Cancer 2002;35:11-6.
26. Sale S, Sung R, Shen P, et al. Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers. Mol Cancer Ther 2002;1:215-25.
27. Lamendola DE, Duan Z, Penson RT, et al. Tubulin mutations are rare in human ovarian carcinoma. Anticancer Res 2003;23:681-6.
28. Kavallaris M, Burkhardt CA, Horwitz SB. Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to taxol. Br J Cancer 1999;80:1020-5.
29. Hari M, Yang H, Zeng C, et al. Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel. Cell Motil Cytoskeleton 2003;56:45-56.